Gsk: Internal Innovation Strategy

Answer 2 …… Glaxosmithkline (GSK ), a research and development firm seeking to be excel in internal innovation through research on eight therapy areas- biopharmaceuticals, immune-inflammation, infectious diseases, metabolic pathways, neuroscience, oncology, ophthalmology and respiratory. To address these areas the firm in 2008 created 70 Discovery Performance Unit (DPUs) for future growth of the company. These 70 DPUs can affect the implementation effort in following ways to achieve success in the field of internal innovation which result in development of vaccines for the diseases identified by the World Health Organization. a) In order to reduce the time in screening and evaluating more ideas and product, so that judgments can be on which innovation to initiate support for or continue to promote it for marketable product. b) In addition to development of new product for external use, GSK will be able to make changes in its R & D structure to improve the technology for internal use. c) Since 70 DPUs are made of small and compact integrated team, who are working together for a multiple defined projects. Hence, these cross- functional teams would be able to share lessons and build a knowledge based culture which result in enhancing skills of individual in order to develop new forms of old product with technological innovation. d) As we aware that approx 14850 people are directly engage in research to discover new medicines. In order to generate and aligning strong personal belief and values in every employee behavior in respect of organizations values and goal, so that effort can be made to produce new ideas that add value in the market place. Secondly, allows you to allocate ample resources to critical activities in order to achieve defined goal to outperform its competition.

To ensure that implementation of 70 DPUs on eight therapy is successful, I would like to suggest that GSK should introduce “Reward &